Modern mass spectrometry developments hold significant potential for the discovery and sensitive detection of innovative (sets of) biomarkers which will allow rapid and accurate diagnosis of multiple disorders simultaneously in a single patient’s small-volume sample.

ProteoFormiX is running a mass spectrometry-based top-down proteomics technology platform to identify such disease-associated proteoforms (e.g., peptides) in clinically sampled human tissues and biofluids.


ProteoFormiX was founded by Prof. Dr. Peter Verhaert in 2017. The company resides at JLABS@BE, the European Johnson & Johnson Innovation Center.

company profile


About ProteoFormiX

Projects & Services

Presence at International Scientific Meetings

Advisory Board

News / Highlights

Partnerships / Industrial Support

In the Media